Affiliation:
1. First Affiliated Hospital of Zhengzhou University
Abstract
Abstract
Purpose The aim was to investigate the safety and efficacy of 125I brachytherapy as consolidative local therapy for patients with synchonous oligometastatic non-small cell lung cancer (sOM-NSCLC) without progression after first-line chemotherapy plus PD-1 inhibitors treatment consolidative percutaneous.
Materials and Methods We retrospective analyzed 38 patients (31 male [81.6%], 7 women [18.4%], median age 66 years,range:[47-77 years] ) with sOM-NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genetic aberrations, who were treated with first-line chemotherapy plus PD-1inhibitors 4-6 cycles followed by consolidative CT-guided 125I brachytherapy and maintenance therapy with PD-1 inhibitors in our hospital between June 2020 to June 2022 . Treatment efficacy and adverse events were evaluated.
Results At the cutoff date of December 2022, the median follow-up time was 16.5 months (range: 7-28 months). 26 patients had progressive disease (PD) and 6 patients had died, the median progression free survival (mPFS) was 17.0 months (95% CI, 12.0-22.0 months). 1 patient had complete response (CR), 26 patients had partial response (PR), 10 patients had stable disease (SD), 1 patient had progressive disease (PD). The best objective response rate (ORR) was 71.1%. Patients with PD-L1 positive cancers and 1-3 metastatic lesions had longer PFS than patients with PD-L1 negative and 4-5 metastatic lesions (18.0 months vs 12 months, p=0.038) and (17.0 months vs 9 months, p=0.010 ). The lymph node stage was an independent prognostic factor for PFS (19 months vs 9 months, p=0.002).
Conclusion 125I brachytherapy is a safe, feasible and valuable consolidative treatment for consideration in patients with sOM-NSCLC after first line chemotherapy plus PD-1 inhibitors treatment.
Publisher
Research Square Platform LLC